Morgan Stanley
AARD

Morgan Stanley’s Aardvark Therapeutics AARD Stock Holding History

Morgan Stanley’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$66.2K Sell
17,562
-60,392
-77% -$626K ﹤0.01% 6307
2025
Q4 		$1.02M Buy
77,954
+9,492
+14% +$118K ﹤0.01% 5179
2025
Q3 		$910K Buy
68,462
+59,502
+664% +$671K ﹤0.01% 5218
2025
Q2 		$121K Buy
8,960
+6,742
+304% +$69.5K ﹤0.01% 6064
2025
Q1 		$16.7K Buy
+2,218
New +$24.9K ﹤0.01% 6635

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley's AARD Position: Q1 2026 in Review

Morgan Stanley reduced its Aardvark Therapeutics (AARD) stake by 77% in Q1 2026, selling an estimated $626K and leaving 17,562 shares worth $66.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6307.

Morgan Stanley first reported a position in AARD in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.02M in Q4 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Morgan Stanley held 17,562 shares of Aardvark Therapeutics worth $66.2K as of Q1 2026.
  • Morgan Stanley sold 60,392 Aardvark Therapeutics shares in Q1 2026, an estimated $626K.
  • Aardvark Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6307 holding.
  • Morgan Stanley first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Morgan Stanley's Aardvark Therapeutics position peaked at $1.02M in Q4 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.